Can-Fite BioPharma Surges in Premarket Trading After Securing Brazilian Patent for Sexual Dysfunction Therapy

MT Newswires Live

2025/12/26

Can-Fite BioPharma, an Israel-based biotech company, surged in premarket trading Friday after receiving a patent from the Brazilian Patent Office for its A3 adenosine receptor, or A3AR, drugs to treat sexual dysfunction.

Sexual dysfunction can be linked to blood flow, inflammation, and metabolic issues. Can-Fite's research showed that activating the A3 adenosine receptor may affect key body signals that control sexual function, supporting the use of this treatment.

The company said the patent could pave the way for partnerships or sales opportunities in Latin America. Can-Fite is also developing its A3AR drugs for cancer, inflammatory diseases, and other conditions.

Shares of Can-Fite jumped more than 50% in recent pre-market trading.

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/news/2594299698"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2594299698\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2594299698?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-12-26 21:05","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2594299698","market":"fut","top_or_hot":-1,"title":"Can-Fite BioPharma Surges in Premarket Trading After Securing Brazilian Patent for Sexual Dysfunction Therapy","media":"MT Newswires Live","content":"<html><body><p> Can-Fite BioPharma, an Israel-based biotech company, surged in  premarket trading Friday after receiving a patent from the Brazilian Patent Office for its A3 adenosine receptor, or A3AR, drugs to treat sexual dysfunction.</p><p>Sexual dysfunction can be linked to blood flow, inflammation, and metabolic issues. Can-Fite's research showed that activating the A3 adenosine receptor may affect key body signals that control sexual function, supporting the use of this treatment.</p><p>The company said the patent could pave the way for partnerships or sales opportunities in Latin America. Can-Fite is also developing its A3AR drugs for cancer, inflammatory diseases, and other conditions.</p><p>Shares of Can-Fite jumped more than 50% in recent pre-market trading.</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Can-Fite BioPharma Surges in Premarket Trading After Securing Brazilian Patent for Sexual Dysfunction Therapy</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nCan-Fite BioPharma Surges in Premarket Trading After Securing Brazilian Patent for Sexual Dysfunction Therapy\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time\">2025-12-26 21:05</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p> Can-Fite BioPharma, an Israel-based biotech company, surged in  premarket trading Friday after receiving a patent from the Brazilian Patent Office for its A3 adenosine receptor, or A3AR, drugs to treat sexual dysfunction.</p><p>Sexual dysfunction can be linked to blood flow, inflammation, and metabolic issues. Can-Fite's research showed that activating the A3 adenosine receptor may affect key body signals that control sexual function, supporting the use of this treatment.</p><p>The company said the patent could pave the way for partnerships or sales opportunities in Latin America. Can-Fite is also developing its A3AR drugs for cancer, inflammatory diseases, and other conditions.</p><p>Shares of Can-Fite jumped more than 50% in recent pre-market trading.</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"CANF","symbol_name":"Can-Fite Biopharma Ltd","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2594299698","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2594299698","pubTimestamp":1766754305,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Can-Fite BioPharma, an Israel-based biotech company, surged in  premarket trading Friday after receiving a patent from the Brazilian Patent Office for its A3 adenosine receptor, or A3AR, drugs to treat sexual dysfunction.Sexual dysfunction can be linked to blood flow, inflammation, and metabolic issues. Can-Fite's research showed that activating the A3 adenosine receptor may affect key body signals that control sexual function, supporting the use of this treatment.The company said the patent could pave the way for partnerships or sales opportunities in Latin America. Can-Fite is also developing its A3AR drugs for cancer, inflammatory diseases, and other conditions.Shares of Can-Fite jumped more than 50% in recent pre-market trading.","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"CANF":"Can-Fite Biopharma Ltd","BK4139":"生物科技"},"translate_title":"Can-Fite BioPharma获得巴西性功能障碍治疗专利后盘前交易飙升","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"CANF":0.9},"content_text":"Can-Fite BioPharma, an Israel-based biotech company, surged in  premarket trading Friday after receiving a patent from the Brazilian Patent Office for its A3 adenosine receptor, or A3AR, drugs to treat sexual dysfunction.Sexual dysfunction can be linked to blood flow, inflammation, and metabolic issues. Can-Fite's research showed that activating the A3 adenosine receptor may affect key body signals that control sexual function, supporting the use of this treatment.The company said the patent could pave the way for partnerships or sales opportunities in Latin America. Can-Fite is also developing its A3AR drugs for cancer, inflammatory diseases, and other conditions.Shares of Can-Fite jumped more than 50% in recent pre-market trading.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1,"need_auth":false,"code":"91000000","status":"200"}}}